Drug discovery: in silico dry data can bypass biological wet data?

The recent and extraordinary increase in computer power, along with the availability of efficient algorithms based on artificial intelligence prompted a wide number of unexperienced scientists to challenge the complex and yet competitive world of the drug discovery pretending to identify new hits with the sole use of computer aided drug design (CADD). Does the golden era of dry data risk to shadow the importance of wet data and to forget that in silico and biological data need each other in successful preclinical drug discovery programs?